You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 56 No. 5, May 1999 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (21)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Epilepsy
 •Pediatric Neurology
 •Seizures, Nonepileptic
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Open Comparative Long-term Study of Vigabatrin vs Carbamazepine in Newly Diagnosed Partial Seizures in Children

Nelia Zamponi, MD; Cesare Cardinali, MD

Arch Neurol. 1999;56:605-607.

Objective  To compare vigabatrin with carbamazepine as monotherapy in newly diagnosed children with partial epilepsy in order to evaluate the efficacy and tolerability of both drugs.

Design  Open and randomized with a 2-year follow-up period.

Setting  The Infantile Neuropsychiatric Division of the Regional Pediatric Hospital, Ancona, Italy.

Patients  Seventy children with newly diagnosed partial epilepsy were treated with vigabatrin (38 patients) or carbamazepine (32 patients).

Intervention  Vigabatrin, 50 to 60 mg/kg per day, or carbamazepine, 15 to 20 mg/kg per day, split into twice-a-day doses.

Outcome Measures  The efficacy and tolerability of vigabatrin were compared with those of the standard treatment (carbamazepine) for this patient group.

Results  The efficacy of vigabatrin and carbamazepine was similar, with the suggestion of a better side effect profile with vigabatrin.

Conclusions  Vigabatrin monotherapy should be considered as a monotherapeutic treatment option in patients with newly diagnosed epilepsy. However, more studies are needed to evaluate other issues of concern, such as the cognitive and behavioral adverse effects of antiepileptic drugs, to determine the most suitable therapy.


From the Department of Pediatric Neurology, "G. Salesi" Children's Hospital, Ancona, Italy.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Behavioral and Psychiatric Adverse Events Associated With Antiepileptic Drugs Commonly Used in Pediatric Patients
Glauser
J Child Neurol 2004;19:S25-S38.
ABSTRACT  

Cognitive side effects of antiepileptic drugs in children
Loring and Meador
Neurology 2004;62:872-877.
ABSTRACT | FULL TEXT  

Behavioral and Psychiatric Adverse Events Associated With Antiepileptic Drugs Commonly Used in Pediatric Patients
Glauser
J Child Neurol 2004;19:S25-S38.
ABSTRACT  

Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy
Kwan and Brodie
Neurology 2003;60:S2-12.
ABSTRACT | FULL TEXT  

A controlled study of vigabatrin and visual abnormalities
Manuchehri et al.
Br J Ophthalmol 2000;84:499-505.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.